PharmNovo successfully completes phase I study with lead candidate PN6047
The Swedish pharmaceutical company PharmNovo is pleased to announce the completion of the phase I study of the drug candidate PN6047 for neuropathic pain. The headline results of the study show that PN6047 is proven safe and tolerable at doses predicted to be effective.PharmNovo is a clinical-phase pharmaceutical company dedicated to developing safe and effective treatments for neuropathic pain. The company’s lead drug candidate, PN6047, has successfully completed the phase I study, demonstrating both safety and tolerability at doses expected to be efficacious. Furthermore, the study